Clinical Report: Inflammatory Immune Markers and Heart Failure Outcomes
Overview
This study identifies immune-inflammatory markers as significant predictors of heart failure (HF) incidence and mortality. The inflammatory burden index (IBI) emerged as the most robust biomarker, highlighting its potential for risk stratification in HF management.
Background
Heart failure is a major global health issue, with increasing prevalence and high mortality rates. Chronic inflammation plays a critical role in the pathophysiology of HF, making the identification of reliable biomarkers essential for early detection and management. Understanding the predictive value of various immune-inflammatory indices can enhance risk stratification and improve patient outcomes.
Elevated levels of SII, SIRI, AISI, IBI, and NLR are associated with increased HF incidence.
The IBI shows the strongest association with HF risk, with an 86% higher risk in the highest quintile.
Higher CALLY levels correlate with a lower risk of HF and improved survival among HF patients.
SIRI, AISI, IBI, and NLR positively correlate with all-cause mortality in established HF patients.
ROC analyses indicate that IBI has superior predictive accuracy for both incident HF and mortality.
Clinical Implications
Clinicians should consider the use of immune-inflammatory markers, particularly the IBI, for risk stratification in patients at risk for heart failure. These markers may aid in identifying individuals who would benefit from early intervention and tailored management strategies.
Conclusion
The study underscores the importance of immune-inflammatory markers in predicting heart failure outcomes, with the IBI emerging as a key tool for clinical risk assessment. Further research is warranted to integrate these findings into routine clinical practice.
